Adagio Medical Seeks FDA Nod for Ventricular Ablation System
Event summary
- Adagio Medical submitted a Premarket Approval (PMA) application to the FDA for its vCLAS Ventricular Ablation System to treat ventricular tachycardia (VT).
- The submission is backed by the FULCRUM-VT trial, which enrolled 209 patients across 20 electrophysiology centers.
- The trial reported 97.4% acute clinical success and 84.3% freedom from ICD shock at 6 months.
- vCLAS demonstrated a 78% reduction or elimination of anti-arrhythmic drug use and 2.4% major adverse events.
The big picture
Adagio Medical's PMA submission for the vCLAS system marks a significant step in expanding treatment options for patients with ventricular tachycardia. The company's proprietary ULTA technology aims to address a critical gap in the market, particularly for patients with both ischemic and non-ischemic structural heart disease. The success of the FULCRUM-VT trial positions Adagio to potentially become a key player in the cardiac arrhythmia treatment space, pending FDA approval.
What we're watching
- Regulatory Timeline
- The pace at which the FDA reviews Adagio's PMA application and the potential approval timeline for the vCLAS system.
- Market Adoption
- Whether the vCLAS system can gain traction among electrophysiologists and address the unmet need in VT ablation.
- Competitive Positioning
- How Adagio's endocardial-only approach differentiates it from existing solutions in the VT ablation market.
Related topics